Brepocitinib

Brepocitinib is an orally available, selective inhibitor of non-receptor tyrosine-protein kinase TYK2 (tyrosine kinase 2) and tyrosine-protein kinase JAK1 (Janus kinase 1; JAK1) with potential immunomodulatory and anti-inflammatory activities. Upon oral administration, brepocitinib selectively binds to and inhibits the activation of TYK2 and JAK1, thereby disrupting TYK2 and JAK-1-dependent cytokine signaling. It is grouped under the following drug class(es): JAK inhibitors and Tyrosine Kinase Inhibitors. Its source/manufacturing origin is listed as synthetic. Other names for this substance include Methanone, ((1S)-2, 2-difluorocyclopropyl)(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)-4-pyrimidinyl)-3, 8-diazabicyclo(3.2.1)oct-8-yl)- and TYK2/JAK1 Inhibitor PF-06700841. Its PubChem CID is 118878093.

CAS No 1883299-62-4
Molecular Formula C18H21F2N7O
Molecular Weight 389.4 g/mol
Synonyms [(1S)-2,2-difluorocyclopropyl]-[(1S,5R)-3-[2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone

Frequently Asked Questions